Nectar Lifesciences Limited

NSE NECLIFE.NS

Nectar Lifesciences Limited Free Cash Flow Yield on January 31, 2025: 26.71%

Nectar Lifesciences Limited Free Cash Flow Yield is 26.71% on January 31, 2025, a 108.97% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Nectar Lifesciences Limited 52-week high Free Cash Flow Yield is 30.74% on July 19, 2024, which is 15.09% above the current Free Cash Flow Yield.
  • Nectar Lifesciences Limited 52-week low Free Cash Flow Yield is 10.53% on February 20, 2024, which is -60.59% below the current Free Cash Flow Yield.
  • Nectar Lifesciences Limited average Free Cash Flow Yield for the last 52 weeks is 22.87%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
SV Wall Street
NSE: NECLIFE.NS

Nectar Lifesciences Limited

CEO Mr. Amit Chadah
IPO Date July 18, 2005
Location India
Headquarters SCO 38-39
Employees 1,686
Sector Health Care
Industries
Description

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

Similar companies

KOPRAN.NS

Kopran Limited

USD 2.10

-2.71%

MOREPENLAB.NS

Morepen Laboratories Limited

USD 0.75

4.08%

SUVEN.NS

Suven Life Sciences Limited

USD 1.48

10.54%

MARKSANS.NS

Marksans Pharma Limited

USD 2.78

0.16%

StockViz Staff

February 1, 2025

Any question? Send us an email